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Abstract
Background: Although various pancreaticojejunal duct-to-mucosa anastomosis methods have been developed to
reduce the postoperative risks of pancreaticoduodenectomy, pancreatic fistula remains the most serious
complication with a high incident rate. The aim of this study is to compare the safety and effectiveness of one-layer
and two-layer duct-to-mucosa pancreaticojejunostomy in patients undergoing pancreaticoduodenectomy.
Methods/design: In this study, adult patients who sign consent forms will be recruited and scheduled for elective
pancreaticoduodenectomy. One hundred and fourteen patients will be included and randomized before
pancreaticojejunal reconstruction and after resection of the lesion from the pancreatic or periampullary region.
The primary efficacy endpoint is the incident rate of postoperative pancreatic fistula. Statistical analysis will be
based on the intention-to-treat population. Patients will be followed up for 3 months by monitoring for
complications and other adverse events.
Discussion: This prospective, single-center, randomized, single-blinded, two-group parallel trial is designed to
compare one-layer with two-layer duct-to-mucosa anastomosis for pancreaticojejunal anastomosis during elective
pancreaticoduodenectomy.
Trial registration: Clinical Trials.gov: NCT02511951. Registered on 29 July 2015.
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Background
To date, pancreaticoduodenectomy (PD) has been
regarded as the only potentially curative treatment for
pancreatic head and periampullary tumors, including
tumors in the ampullary region, distal biliary duct, and
periampullary duodenum [1]. A retrospective study in
which 1000 cases were recruited over the past three
decades showed that PD has become an effective treat-
ment to reduce hospital mortality [2]. Mortality has been
reduced to less than 5 %, but the morbidity remains at
30–50 % [2, 3]. Postoperative pancreatic fistula (POPF)
is one of the most frequent and ominous complications
after PD, and its occurrence reportedly ranges from
2–40 % [4, 5]. Severe POPF prolongs hospital stay and
requires the use of specific treatments, such as the use
of antibiotics, nutritional support, endoscopy, interven-
tional radiology, and/or reoperation, etc. [6]. POPF risk
is increased by many factors including pancreatic tex-
ture, main pancreatic duct diameter, and pancreaticoje-
junal (PJ) anastomotic technique [7–9]. Among these
factors, only anastomotic technique can be improved.
According to the International Study Group of Pancre-
atic Surgery (ISGPS) definition, POPF exists if the drain-
age of any measurable volume of fluid containing
amylase exceeds three times the normal serum value on
or after postoperative day (POD) 3 [10].
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Several anastomotic surgical techniques have been devel-
oped to reduce the incidence of pancreatic fistula in recent
decades, including the duct-to-mucosa method, pancreati-
cogastrostomy, Peng’s binding method, and the “end-to-
end” or “end-to-side” invaginated method. Among these
techniques, the conventional duct-to-mucosa method re-
mains the most popular anastomosis due to its advantages.
The size of the pancreatic remnant is not limited; moreover,
the jejunal lumen and pancreatic remnant lead to easier
anastomosis [11–14].
Compared with two-layer duct-to-mucosa anasto-
mosis, the novel one-layer duct-to-mucosa PJ anasto-
mosis method has been reported to be efficient at
reducing POPF occurrence [15, 16]. However, the two
cited retrospective studies might lead to selection bias.
Because this evidence is insufficient, we will conduct a
randomized controlled trial to verify the superiority of




The aim of this study is to compare the effect of two
duct-to-mucosa PJ anastomotic methods for PD by
assessing factors that are related to mortality or morbid-
ity, including postoperative pancreatic fistula rate, biliary
leakage, postpancreatectomy hemorrhage, and anasto-
mosis time.
Patient involvement
Sample size calculation is based on the primary endpoint:
POPF rate. According to published data, an assumed
absolute risk of 22 % difference in POPF occurrence is the
appropriate basis for the calculation assuming 4.5 % POPF
in the one-layer technique group and 26.7 % in the two-
layer technique group [15, 16]. This calculation yields a
total of 51 patients in each group, which assures a power
of 90 % at a two-sided level of significance of 5 % (NCSS
and PASS 11 (NCSS Statistical Software, Kaysville, UT,
USA)). Assuming an expected withdrawal rate of 10 %
during the trial, 12 additional patients will be included
and randomized; therefore, the total sample size required
is n = 114 patients (Fig. 1) (Additional files 1 and 2).
Eligibility criteria
Inclusion criteria
Patients who meet the following criteria will be included
in the study:
1. Age 18–80 years
2. Elective pancreaticoduodenectomy
3. Provision of informed consent.
Exclusion criteria
Patients who meet any of the following criteria will be
excluded from the study:
Fig. 1 Flow chart according to CONSORT
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1. Patients with any severe cardiopulmonary disease:
American Society of Anesthesiologists (ASA)
classification or ejection fraction below 30 % that
might prolong the postoperative hospital stay
2. Previous pancreatic operation




Patients can withdraw from the trial at their own request
or at the request of their legal representative at any time.
Patients may be removed if, in the investigator’s opinion,
continuation of the trail could be detrimental to the pa-
tient’s well-being or if a PD is not performed due to
technical unresectability, metastatic disease, or other
reasons. Every withdrawal will be recorded in the clinical
report forms (CRFs) and in the patient’s medical case re-
cords. All examinations scheduled for the final trial day
will be performed on all patients and documented. All
data will be analyzed according to the intention-to-treat
(ITT) principle [17].
Ethics, study registration, and consent
The final protocol has been approved by the Ethics Com-
mittee of the Second Affiliated Hospital of Anhui Medical
University (approval number: KY201502). The trial proto-
col has also been registered in the protocol registration
system at ClinicalTrials.gov (identifier: NCT02511951).
All patients will be scheduled only after comprehensive
information concerning the nature, scope, and possible
consequences of the clinical trial has been provided to
them in an understandable way by the investigator. Writ-
ten informed consent for the study will be obtained from
each patient before the operation. The study procedure,
benefits, risks, and data management will be clarified in
detail during the preoperative conversation.
Trial interventions
One-layer duct-to-mucosa PJ anastomosis
For the one-layer technique group, to create the posterior
suturing layers, double needles with a 4–0 Prolene line
(Ethicon, Shanghai, China) will be used; one side of the
needles will be inserted from the posterior inner side of
the pancreatic duct and out through the dorsal paren-
chyma of the pancreatic stump to the posterior surface of
the pancreas at a point approximately 0.5 cm from the cut
edge. The other side of the needles will be started from
the inner side of the jejunum lumen, then pushed through
the subserosa and seromuscular region, and out from the
posterior surface of the bowel (Fig. 2). The anterior sutur-
ing layer will be treated in the same manner. An internal
pancreatic duct stent will be inserted into the duct of the
pancreatic remnant according to its size. Drain tubes will
Fig. 2 The procedure of end-to-side one-layer duct-to-mucosa PJ
anastomosis: the posterior suturing layer
Fig. 3 The anterior suturing layer with duct-to-mucosa
PJ anastomosis
Fig. 4 The procedure of end-to-side two-layer duct-to-mucosa PJ
anastomosis: the seromuscular layer
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be placed anterior and posterior to the anastomosis (one
each) when the anastomosis has been completed (Fig. 3).
Two-layer duct-to-mucosa PJ anastomosis
For the two-layer continuous suture method, the same
double needle and 4–0 Prolene line will be used. First, the
region approximately 1.0 cm from the cutting edge of the
pancreatic remnant will be freed; then, the posterior sur-
face of the pancreatic remnant will be sutured to the sero-
muscular layer of the jejunum using the continuous
suturing method (Fig. 4). The jejunum will be brought
closer to the stump of the pancreas, and a hole of similar
diameter to the main pancreatic duct will be made on the
jejunum near the entrance of the main pancreatic duct.
The posterior wall of the jejunum near the hole will be
sutured to the posterior wall of the pancreatic duct using
the continuous suturing method with Prolene line, and a
suitable internal pancreatic duct stent will then be placed
approximately 4–6 cm into the main duct (Fig. 5). The
interior side of the jejunum and pancreas will be sutured
using the same method. Then, the anterior surface of the
pancreatic remnant and the seromuscular layer of the
jejunum will be tightly sutured using the continuous
method. Drain tubes will be managed as described above.
Primary and secondary endpoints
Primary endpoint
The primary efficacy endpoint of the trial will be the
POPF occurrence rate. POPF is defined by the Inter-
national Study Group of Pancreatic Fistula (ISGPF) as any
measurable volume of drain fluid that contains three times
higher amylase content than the normal upper serum
value, on or after POD 3. Amylase will be assessed on
PODs 1, 3, 5, and 7. Three grades of POPF are determined
according to clinical severity: A, B, and C [10].
Secondary endpoints
Secondary outcomes will be postoperative hospital stay,
anastomosis time, postpancreatectomy hemorrhage, bil-
iary leak, delayed gastric emptying, wound infection,
intra-abdominal fluid collection or abscess, relaparot-
omy, and mortality. Existent ISGPS definitions will be
used to ensure the comparability and generalizability of
the results (Table 1). Postoperative complications will
be graded based on severity according to the Clavien-
Dindo definition [18] (Table 2).
Fig. 5 The procedure of two-layer duct-to-mucosa PJ anastomosis:
duct-to-mucosa layer
Table 1 Definition of secondary endpoints
Secondary endpoint Definition and assessment of outcomes
Anastomosis time Time from beginning to end of PJ anastomosis
Mortality Death due to any cause until 90 days after the operation and the reason
Morbidity Postoperative complications will be recorded until 90 days after operation.
The severity of complications will be graded according to the Clavien-Dindo classification [18]
Postoperative hospital stay Time from day of operation until discharge (days)
Postpancreatectomy
hemorrhage
Evidence of blood loss from drains and/or nasogastric tube, based on ultrasonography,
as defined by ISGPS [19]
Biliary leak Bilirubin concentration in the drain fluid at least three times the serum bilirubin concentration as defined by
International Study Group of Liver Surgery [20]
Delayed gastric emptying Failure to resume solid diet with prolonged need for nasogastric tube as defined by ISGPS [21]
Intra-abdominal fluid
collection
Collection of fluid measuring ≥3 cm associated with clinical or laboratory abnormalities
Wound infection Surgical site infection associated with laparotomy that develops during the initial hospital stay
Pneumonia Presence of a new infiltrate on chest X-ray, as well as following: body temperature >38 °C,
abnormal elevation of white blood cells, or positive sputum, and requiring antibiotic treatment
Abdominal rupture Dehiscence of abnormal closure with need for resuture of the laparotomy during the initial hospital stay
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Type of trial
This is a prospective, randomized, interventional, and
patient-blinded, single-center trial comparing two paral-
lel groups.
Randomization
To achieve intervention groups with comparable known
and unknown risk factors, randomization will be per-
formed. The randomization number will be generated
using computer-generated random numbers with an
allocation ratio of 1:1 (an equal probability of assignment
to either group). All patients will be randomized using
consecutively numbered opaque envelopes that will have
been sealed by the investigators. The envelopes will be
opened before PJ reconstruction and after resection of the
lesion from the pancreatic or periampullary region.
Blinding
Patients and outcome observers will be blinded with re-
spect to the trial intervention. Blinding of the surgeons
and people involved in the operation is not feasible due
to the nature of the interventions.
Data management and quality assurance
An independent study doctor (SBP), who will not be
involved in the treatment and monitoring of the pa-
tients within the operating room, will enter all re-
quired data in the prepared CRF. This CRF will be
completed as soon as possible, preferably on the day of
the patient’s treatment and visit (Table 3). Reasonable
explanations should be given for all missing data.
Complete CRF pages will be checked by the principal
investigator and the responsible monitor with respect
to completeness and plausibility.
Statistical analysis
The two-sided null hypothesis for the primary endpoint
measurement states that both study interventions will lead
to a similar POPF occurrence rate; the alternative hypoth-
esis is that one intervention will perform better than the
other. The null hypothesis will be tested by analyzing the
covariance while adjusting for pancreatic texture (soft or
hard) and main pancreatic duct diameter (<3 mm or
≥3 mm). A binary logistic regression will be applied to
compare the POPF occurrence rates between the groups
after adjusting for other factors. Background characteristics
and surgical outcome measures will be compared using
chi-squared or Fisher’s exact tests for categorical data and
two-tailed t tests or nonparametric Mann–Whitney U tests
for continuous variables. Categorical data will be presented
as frequencies and group percentages, and continuous
variables will be expressed as the means and standard
Table 2 Complication grades according to the Clavien-Dindo
classication schemea
Grade Definition
I Any deviation from the normal postoperative course without
the need for pharmacological treatment or surgical,
endoscopic, and radiological intervention
II Requiring pharmacological treatment with drugs other
than those allowed for
grade I complications
III Requiring surgical, endoscopic, or radiological intervention
IIIa Intervention not under general anesthesia
IIIb Intervention under general anesthesia
IV Life-threatening complication. Requiring intensive
care unit management
IVa Single organ dysfunction
IVb Multi-organ dysfunction
V Death of patient
aThe Clavien-Dindo classification system is reported in detail elsewhere [18]
Table 3 Flow chart of the trial
Screening
Visit 1 Visit 2 Visit 3 Visit 3 Visit 3 Visit 4






Laboratory tests × × × × ×
Trial intervention ×
Intraoperative outcomes ×
Postoperative outcomes × × × ×
aHeight (cm), weight (kg), gender, immunosuppressant medication, antibiotics, chemotherapy
bPostoperative day
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deviations. The homogeneity of two groups will be
described by comparison of the demographic data and
baseline values. All analyses will be performed on an ITT
basis [17]. For the ITT analysis, the data will be processed
for all trial patients in their randomized groups. A P value
< 0.05 will be considered statistically significant. All statis-
tical calculations will be performed using SPSS10.0 (SPSS,
Chicago, IL, USA).
Discussion
Currently, pancreaticoduodenectomy is a routine operation,
and postoperative mortality is less than 5 % [2, 3]. POPF is
among the most frequently encountered complications that
contribute to a high postoperative mortality. Debate regard-
ing the preferred surgical technique for PJ anastomosis has
continued for decades. Many retrospective studies have
suggested that the POPF occurrence rate is reduced by
using a one-layer rather than a two-layer duct-to-mucosa
PJ anastomosis [15, 16]. However, more reliable evidence
should be accumulated to address the advantages and dis-
advantages of both techniques. In this way, the most benefi-
cial technique can be selected for individual patients.
Therefore, the factors affecting the success of one-layer ver-
sus two-layer duct-to-mucosa PJ anastomosis should be
evaluated in this randomized controlled trial to minimize
the POPF rates associated with PD.
Trial status
The trail is currently recruiting patients. All patients
should be recruited by December 2018.
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